Zurcher Kantonalbank Zurich Cantonalbank Has $141,000 Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 46.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,105 shares of the company’s stock after acquiring an additional 8,932 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ImmunityBio were worth $141,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Wealth Effects LLC grew its stake in shares of ImmunityBio by 11.2% in the 4th quarter. Wealth Effects LLC now owns 59,500 shares of the company’s stock valued at $299,000 after purchasing an additional 6,000 shares during the period. Aire Advisors LLC acquired a new position in ImmunityBio during the third quarter worth $25,000. Courier Capital LLC bought a new position in shares of ImmunityBio during the fourth quarter valued at $75,000. SG Americas Securities LLC boosted its stake in shares of ImmunityBio by 45.4% in the 4th quarter. SG Americas Securities LLC now owns 49,005 shares of the company’s stock valued at $246,000 after purchasing an additional 15,308 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in shares of ImmunityBio in the 3rd quarter worth about $26,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Price Performance

NASDAQ IBRX opened at $7.92 on Thursday. The stock’s 50 day simple moving average is $5.81 and its 200 day simple moving average is $4.58. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53. The firm has a market cap of $5.36 billion, a PE ratio of -6.83 and a beta of 1.16.

ImmunityBio (NASDAQ:IBRX) last announced its earnings results on Tuesday, March 19th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The firm had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, equities analysts expect that ImmunityBio, Inc. will post -0.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler boosted their price target on shares of ImmunityBio from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Monday, April 29th.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.